Plasma proteome-driven discovery of therapeutic targets for age-related macular degeneration: a multi-omics mendelian randomization framework
Molecular Genetics and Genomics · 2026-12 · 301 (1)
DOI: 10.1007/s00438-026-02544-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Genetics and Genomics, online erschienen am 07.11.2026. Verfasst von Zhaoyu Xiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Eye Institute and Department of Ophthalmology, Eye and ENT Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Macular Degeneration, Proteome, Mendelian Randomization Analysis, Blood Proteins. Die Arbeit nennt 44 Literaturangaben. Gefördert von: National Clinical Key Specialty Construction Project, National Key Research and Development Program of China, the National Natural Science Foundation of China.
Abstract (Originalsprache)
This study aimed to prioritize potential therapeutic candidates for age-related macular degeneration (AMD) using an integrated multi-omics Mendelian randomization (MR) framework. We performed two-sample MR using 2,816 cis-pQTLs from four proteome-wide association studies to identify AMD-associated plasma proteins. Validation included summary-based MR (SMR), colocalization, protein-protein interaction analysis, pathway enrichment, retinal expression profiling, and druggability assessment. We identified 22 AMD-associated proteins, including both known (e.g., CFB, APOE, C3) and novel candidates (e.g., CTRL, LCAT, TNFRSF10A). Four targets (C3, CTRL, LCAT, TNFRSF10A) were prioritized as Tier 1 candidates based on consistent MR and colocalization evidence. These targets were enriched in complement activation, coagulation, and lipid metabolism pathways. This study proposed 22 potential therapeutic targets for AMD, with C3, CTRL, LCAT, and TNFRSF10A representing high-confidence candidates for further mechanistic and clinical investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eye Institute and Department of Ophthalmology, Eye and ENT Hospital, Fudan University, Shanghai, China.
- Department of Ophthalmology, Shanghai First People's Hospital/Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100, Haining Road, Shanghai, China.
- National Clinical Research Center for Eye Diseases, Shanghai, China.
- Shanghai Key Laboratory of Fundus Diseases, Shanghai, China.
- School of Clinical Medicine, Jiamusi University, Jiamusi, China.
- Department of Ophthalmology, Shanghai First People's Hospital/Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100, Haining Road, Shanghai, China. 1145524313@qq.com.
Förderung
- National Clinical Key Specialty Construction Project
- National Key Research and Development Program of China
- the National Natural Science Foundation of China
- Shanghai Hospital Development Center Foundation
- Shanghai Municipal Hospital Ophthalmology Specialist Alliance
- Zhejiang Medicine and Health Science and Technology Project
- Ningbo Clinical Medical Research Center for Ophthalmology
Zitieren
APA
Xiang, Z., Huang, W., Zhao, X., Zhou, M., Huang, X., & Wang, S. (2026). Plasma proteome-driven discovery of therapeutic targets for age-related macular degeneration: a multi-omics mendelian randomization framework. Molecular Genetics and Genomics, 301(1). https://doi.org/10.1007/s00438-026-02544-7
Vancouver
Xiang Z, Huang W, Zhao X, Zhou M, Huang X, Wang S. Plasma proteome-driven discovery of therapeutic targets for age-related macular degeneration: a multi-omics mendelian randomization framework. Molecular Genetics and Genomics. 2026;301(1). doi:10.1007/s00438-026-02544-7
BibTeX
@article{Xiang2026,
author = {Xiang, Zhaoyu and Huang, Wenjia and Zhao, Xiaohuan and Zhou, Minwen and Huang, Xiaoxu and Wang, Shiming},
title = {Plasma proteome-driven discovery of therapeutic targets for age-related macular degeneration: a multi-omics mendelian randomization framework},
journal = {Molecular Genetics and Genomics},
year = {2026},
volume = {301},
number = {1},
doi = {10.1007/s00438-026-02544-7}
}
EUVIMED